A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2 Positive Breast Cancer.

Trial Profile

A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2 Positive Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs Neratinib (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Mar 2017 This trial is completed in Portugal. (End date: 25 Nov 2016)
    • 19 Dec 2016 This trial has been completed in Spain
    • 07 Dec 2016 Results of biomarker analysis published in a Puma Biotechnology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top